MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

Resistance to endocrine therapy in estrogen receptor-positive (ER(+)) breast cancer is a major clinical problem with poorly understood mechanisms. There is an unmet need for prognostic and predictive biomarkers to allow appropriate therapeutic targeting. We evaluated the mechanism by which minichrom...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:NPJ Breast Cancer
Hlavní autoři: Løkkegaard, Sanne, Elias, Daniel, Alves, Carla L., Bennetzen, Martin V., Lænkholm, Anne-Vibeke, Bak, Martin, Gjerstorff, Morten F., Johansen, Lene E., Vever, Henriette, Bjerre, Christina, Kirkegaard, Tove, Nordenskjöld, Bo, Fornander, Tommy, Stål, Olle, Lindström, Linda S., Esserman, Laura J., Lykkesfeldt, Anne E., Andersen, Jens S., Leth-Larsen, Rikke, Ditzel, Henrik J.
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7782683/
https://ncbi.nlm.nih.gov/pubmed/33398005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-020-00210-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky